Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | ENTPD2 | Q9Y5L3 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17191712 | 0.91 | MEN1 (0.32) | CYP3A4CYP2C9MEN1KMT2A | |
| SCHEMBL17191717 | 0.85 | SLC28A1 (0.34) | — | |
| SCHEMBL17807707 | 0.81 | SLC28A1 (0.32) | — | |
| SCHEMBL860749 | 0.81 | SLC28A1 (0.32) | — | |
| SCHEMBL15782468 | 0.81 | SLC28A1 (0.32) | — | |
| SCHEMBL10238922 | 0.81 | SLC28A1 (0.32) | — | |
| SCHEMBL15765635 | 0.79 | SLC28A1 (0.31) | — | |
| SCHEMBL1591858 | 0.79 | SLC28A1 (0.31) | — | |
| SCHEMBL25741344 | 0.78 | — | — | |
| SCHEMBL15739610 | 0.74 | SLC28A1 (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230201236-A1 | SPIROCYCLIC NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF HEPATITIS E | Janssen Pharmaceuticals, Inc. | 2023-06-29 | — | — | US | disclosed |
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | JANSSEN PHARMACEUTICA NV (BE) | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139524-A1 | SPIROTHIETANE NUCLEOSIDES | SAMHD1, SLC28A1, SLC28A2 | CYP3A4 246/4885CYP2C9 305/4885ENTPD2 712/4885 |
| US-20230201236-A1 | SPIROCYCLIC NUCLEOSIDE ANALOGUES FOR THE TREATMENT OF HEPATITIS E | HAVCR2, NME2, SLC10A1 | CYP3A4 1033/4885CYP2C9 1377/4885ENTPD2 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.